Evidence map›Paper›PMID 32883348›Full record

ArticleJournal of neuroinflammation2020

Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.

Sven Jarius, Hannah Pellkofer, Nadja Siebert, Mirjam Korporal-Kuhnke, Martin W Hümmert, Marius Ringelstein, Paulus S Rommer, Ilya Ayzenberg, Klemens Ruprecht, Luisa Klotz and 20 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 16 institutions in 3 countries.

Sven JariusMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.
Hannah PellkoferInstitute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.
Nadja SiebertDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Mirjam Korporal-KuhnkeMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Martin W HümmertDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Marius RingelsteinDepartment of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Paulus S RommerInstitute of Neurology, Medical University of Vienna, Vienna, Austria.
Ilya AyzenbergDepartment of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Klemens RuprechtDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Luisa KlotzDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Nasrin AsgariDepartment of Regional Health Research, Odense, Denmark.
Tobias ZrzavyInstitute of Neurology, Medical University of Vienna, Vienna, Austria.
Romana HöftbergerInstitute of Neurology, Medical University of Vienna, Vienna, Austria.
Rafik TobiaDepartment of Neuropathology, University of Göttingen, Göttingen, Germany.
Mathias ButtmannCaritas Hospital Bad Mergentheim, Bad Mergentheim, Germany.
Kai FechnerEuroimmun AG, Lübeck, Germany.
Kathrin SchandaDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
Martin WeberDepartment of Neuropathology, University of Göttingen, Göttingen, Germany.
Susanna AsseyerDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jürgen HaasMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Christian LechnerDivision of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
Ingo KleiterDepartment of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Orhan AktasDepartment of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Corinna TrebstDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Kevin RostasyDepartment of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Witten, Germany.
Markus ReindlDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
Tania KümpfelInstitute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.
Friedemann PaulDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Brigitte WildemannMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
in cooperation with the Neuromyelitis Optica Study Group (NEMOS)
Heidelberg University · DECharité - Universitätsmedizin Berlin · DEInnsbruck Medical University · ATMedical University of Vienna · ATHeinrich Heine University Düsseldorf · DELudwig-Maximilians-Universität München · DEMedizinische Hochschule Hannover · DEUniversity of Göttingen · DECaritas-Krankenhaus Bad Mergentheim · DEEuroimmun Medizinische Labordiagnostika (Germany) · DEMax Delbrück Center · DERuhr University Bochum · DESt. Josef-Hospital · DEUniversity Hospital Münster · DEUniversity of Southern Denmark · DKWitten/Herdecke University · DE

Funding

Baden-Württemberg Ministry of Science, Research and the Arts n/aDeutsche Forschungsgemeinschaft n/aDeutsche Forschungsgemeinschaft (DFG Exc 257) n/aDietmar Hopp Stiftung n/aGerman Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis) n/aJubilaeumsfonds of the Austrian National Bank 14158 and 15918Merck Serono Germany n/aRuprecht-Karls-Universität Heidelberg n/a
6 · The paper itself

Abstract

backgroundNew-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD).

objectiveTo describe systematically the CSF profile in MOG-EM. MATERIAL AND

methodsCytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively.

resultsMost strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood-CSF barrier dysfunction was present also during remission in a substantial number of patients.

conclusionMOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.

Indexed as

AdolescentAdultAgedAutoantibodiesEncephalomyelitisFemaleHumansImmunoglobulinsMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinRetrospective StudiesSpinal PunctureYoung AdultAutoantibodiesImmunoglobulinsMyelin-Oligodendrocyte GlycoproteinAcute disseminated encephalomyelitis (ADEM)AntibodiesCerebrospinal fluidEncephalomyelitisLumbar punctureMOG antibody-associated disease (MOGAD)Multiple sclerosis (MS)Myelin oligodendrocyte glycoprotein (MOG)Neuromyelitis optica (Devic syndrome)Oligoclonal bandsOptic neuritisTransverse myelitis

Identifiers

PMID32883348
PMCPMC7470615
OpenAlexW3082085208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.